By 2020, osimertinib had already been shown to be significantly superior to first-generation EGFR TKIs not only for progression-free survival (PFS)5 but also for OS6 as first-line treatment for advanced EGFRm+ NSCLC and was the first-line standard of care in this setting. This evidence concerns the gene EGFR and non-small cell lung carcinoma.